Auron Therapeutics Showcases Innovative AUTX-703 Data
Auron Therapeutics, a pioneering biotechnology firm, is carving its niche in the arena of cancer treatment by unveiling promising preclinical insights into its lead program, AUTX-703. This innovative drug is set to take center stage at the 36th EORTC-NCI-AACR (ENA) Symposium, scheduled to occur in late October. The symposium will take place from October 23 to 25, providing a platform for researchers and industry leaders to exchange groundbreaking discoveries in oncology.
Understanding the Significance of AUTX-703
AUTX-703 is designed to target KAT2A and KAT2B, which are histone acetyltransferases implicated in various tumor types, especially small cell lung cancer (SCLC). By effectively inhibiting these proteins, Auron aims to disrupt the oncogenic cell states that contribute to tumor development. The presentation at the ENA will showcase both in vitro and in vivo data, highlighting the drug's potential to induce significant cellular changes and curtail tumor growth.
Details of the Poster Presentation
Auron's poster presentation will feature essential information about their findings:
- Abstract Title: AUTX-703, a Novel and Potent KAT2A and KAT2B Protein Degrader, Induces Profound Cell State Changes and Inhibits Growth on Small Cell Lung Cancer (SCLC) Model Systems
- Poster Session: Molecular Targeted Agents
- Session Date and Time: Wednesday, October 23, 12:00 - 7:00 p.m. CET
About Auron Therapeutics
Founded with a mission at its core, Auron Therapeutics stands out as a patient-oriented company leveraging its cutting-edge AURIGIN™ platform. This platform utilizes artificial intelligence and machine learning to discern the differences between normal and cancerous cell states. Through this advanced analysis, Auron aims to pinpoint novel cancer targets and streamline the development of effective therapies. Currently, the company is focused on building a comprehensive pipeline of targeted therapies, led by the promising AUTX-703.
The Future of Cancer Therapies
As Auron prepares to file an Investigational New Drug (IND) application by the end of the year, there is an air of anticipation surrounding the clinical development poised to commence in early 2025. With the focus on both solid tumors like small cell lung cancer and neuroendocrine prostate cancer, as well as hematologic malignancies such as acute myeloid leukemia, Auron is committed to enhancing cancer treatment outcomes. The company's strategic direction emphasizes a thorough understanding of the oncogenic cell environment, which is essential for developing therapies that can make meaningful impacts in patients' lives.
Investor Contact Information
Auron Therapeutics understands the importance of maintaining open communication with stakeholders. For inquiries, investors can reach out to:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
Frequently Asked Questions
What is AUTX-703?
AUTX-703 is a novel targeted therapy developed by Auron Therapeutics targeting KAT2A and KAT2B, which are crucial in various tumor types.
What will be presented at the ENA Symposium?
Auron will present preclinical data demonstrating the efficacy of AUTX-703 in modifying cancer cell states and inhibiting tumor growth.
When is the ENA Symposium?
The ENA Symposium will be held from October 23-25, featuring innovative research and developments in the field of oncology.
What types of cancers is AUTX-703 targeting?
AUTX-703 is aimed at treating solid tumors, including small cell lung cancer and neuroendocrine prostate cancer, along with certain blood cancers.
How does Auron's AURIGIN platform contribute to cancer research?
The AURIGIN platform uses AI to identify differences between healthy and cancerous cells, allowing for the discovery of novel therapeutic targets and biomarkers.
